Literature DB >> 11553548

Effect on polymorphonuclear cell function of a human-specific cytotoxin, intermedilysin, expressed by Streptococcus intermedius.

M G Macey1, R A Whiley, L Miller, H Nagamune.   

Abstract

Streptococcus intermedius is a member of the normal flora of the mouth but is also an opportunistic pathogen associated with purulent infections at oral and nonoral sites. Intermedilysin (ILY) has been shown to be a cytolysin capable of generating pores in the cell membrane of erythrocytes demonstrable by electron microscopy. This effect has been shown to be specific for human cells. Since polymorphonuclear cells (PMNs) are the main cell involved in innate immunity we investigated the effect of purified intermedilysin from Streptococcus intermedius on PMN function. Active ILY at a concentration of 40 ng/microl caused a significant decrease in the number of intact PMNs after 60 min. The active cytolysin, when compared with heat-inactivated ILY, did not appear to be chemotactic for the PMNs but did cause an increase in intracellular calcium, with increased cell surface CD11b expression, metabolic burst, and phagocytosis of Staphylococcus aureus. These findings may have implications for the role of ILY in deep-seated abscesses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553548      PMCID: PMC98739          DOI: 10.1128/IAI.69.10.6102-6109.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

Review 1.  Integrin-mediated signaling in human neutrophil functioning.

Authors:  M A Williams; J S Solomkin
Journal:  J Leukoc Biol       Date:  1999-06       Impact factor: 4.962

2.  A simple flow cytometric procedure for the determination of surface antigens on unfixed leucocytes in whole blood.

Authors:  D A McCarthy; M G Macey
Journal:  J Immunol Methods       Date:  1993-08-09       Impact factor: 2.303

3.  Haemolytic activity of the Streptococcus milleri group' and relationship between haemolysis restricted to human red blood cells and pathogenicity in S. intermedius.

Authors:  J A Jacobs; C S Schot; L M Schouls
Journal:  J Med Microbiol       Date:  2000-01       Impact factor: 2.472

4.  Distribution of the intermedilysin gene among the anginosus group streptococci and correlation between intermedilysin production and deep-seated infection with Streptococcus intermedius.

Authors:  H Nagamune; R A Whiley; T Goto; Y Inai; T Maeda; J M Hardie; H Kourai
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

5.  Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin.

Authors:  J C Paton; A Ferrante
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

6.  Effects of pneumolysin on human polymorphonuclear leukocytes and platelets.

Authors:  M K Johnson; D Boese-Marrazzo; W A Pierce
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

7.  Streptococcus intermedius, Streptococcus constellatus, and Streptococcus anginosus (the Streptococcus milleri group): association with different body sites and clinical infections.

Authors:  R A Whiley; D Beighton; T G Winstanley; H Y Fraser; J M Hardie
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

8.  Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes.

Authors:  S Houldsworth; P W Andrew; T J Mitchell
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

9.  Emended descriptions and recognition of Streptococcus constellatus, Streptococcus intermedius, and Streptococcus anginosus as distinct species.

Authors:  R A Whiley; D Beighton
Journal:  Int J Syst Bacteriol       Date:  1991-01

10.  The ex vivo function and expression of function-associated antigens of peripheral blood neutrophils and monocytes.

Authors:  M G Macey; D A McCarthy; A C Newland
Journal:  Exp Hematol       Date:  1994-09       Impact factor: 3.084

View more
  7 in total

1.  Insights into the action of the superfamily of cholesterol-dependent cytolysins from studies of intermedilysin.

Authors:  Galina Polekhina; Kara Sue Giddings; Rodney K Tweten; Michael W Parker
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-06       Impact factor: 11.205

2.  Pathogenic bacterial species associated with endodontic infection evade innate immune control by disabling neutrophils.

Authors:  Aritsune Matsui; Jun-O Jin; Christopher D Johnston; Hajime Yamazaki; Yael Houri-Haddad; Susan R Rittling
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

3.  Intermedilysin-receptor interactions during assembly of the pore complex: assembly intermediates increase host cell susceptibility to complement-mediated lysis.

Authors:  Stephanie LaChapelle; Rodney K Tweten; Eileen M Hotze
Journal:  J Biol Chem       Date:  2009-03-16       Impact factor: 5.157

4.  Cervical necrotizing fasciitis: 8-years' experience of microbiology.

Authors:  V Fihman; L Raskine; F Petitpas; J Mateo; R Kania; J Gravisse; M Resche-Rigon; I Farhat; B Berçot; D Payen; M J Sanson-Le Pors; P Herman; A Mebazaa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-04       Impact factor: 3.267

5.  Molecular Basis for Immunity Protein Recognition of a Type VII Secretion System Exported Antibacterial Toxin.

Authors:  Timothy A Klein; Manuel Pazos; Michael G Surette; Waldemar Vollmer; John C Whitney
Journal:  J Mol Biol       Date:  2018-09-05       Impact factor: 5.469

Review 6.  Pharmacological Targeting of Pore-Forming Toxins as Adjunctive Therapy for Invasive Bacterial Infection.

Authors:  Tamara Escajadillo; Victor Nizet
Journal:  Toxins (Basel)       Date:  2018-12-17       Impact factor: 4.546

Review 7.  Streptococcus intermedius causing infective endocarditis and abscesses: a report of three cases and review of the literature.

Authors:  MaryAnn P Tran; Molly Caldwell-McMillan; Walid Khalife; Vincent B Young
Journal:  BMC Infect Dis       Date:  2008-11-10       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.